What question did this study set out to answer?

March 5, 20260 citations

Defining Favorable Prognosis in Bone Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

DKDai KoguchiKitasato University HTHideyasu Tsumura KTKen-ichi TabataKitasato Institute Hospital

Key Points

This research aims to define favorable prognostic factors in bone metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Developed a risk model based on patient characteristics.
Assessed outcomes of patients with varying levels of bone metastases and risk factors.
Compared findings with the existing CHAARTED criteria.
Patients without ≥ 11 bone metastases and high-grade disease may benefit from treatment.
Identified a larger favorable-risk subgroup compared to CHAARTED criteria.
Suggests enhanced precision in treatment selection for prostate cancer patients.

Abstract

This risk model suggests that patients without ≥ 11 BM, ≥ GS9, and ≥ cT3b may benefit from ARSI plus androgen deprivation therapy for mHSPC. Moreover, it identifies a significantly larger favorable-risk subgroup than the CHAARTED criteria, potentially enhancing clinical precision in treatment selection.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Koguchi et al. (Tue,) studied this question.

synapsesocial.com/papers/69a91df9d6127c7a504c162d https://doi.org/https://doi.org/10.1002/pros.70152

AI से पूछें

Bookmark

View Full Paper